The market to commercially harvest and freeze stem cells was launched in 1995 with the first umbilical cord blood bank, and has accelerated dramatically to near (2) million cord blood samples in private storage, and over 600,000 cord blood samples in public storage today. The market through 2014 for cord blood therapeutics is estimated at $13.5 billion and is expected to grow at 6.1% CAGR to reach $19.3 billion by 2020. And currently, of the 4 million US births in 2014, less than 3% have chosen to bank their stem cells presented at this most opportune time.
AmnioChor is a biotech company based in perinatal stem cell technologies that has identified a source and method of acquiring and preserving the amnion placental membrane, and the human stem cells in situ. The amnion membrane is a fragile two cell layer structural tissue that possesses inherent therapeutic qualities, however also comprising a layer of pluripotent Epithelial Stem Cells, and a layer of what AmnioChor has termed, Amnion Derived Stem Cells (ADSC’s), which are Mesenchymal (MSC) in composition. AmnioChor’s Stem Cells differ significantly from cord blood stem cells (Hematopoietic Stem Cells, or HSC’s), and will drive expansion of the private stem cell storage industry and autologous therapies to a completely new level. AmnioChor is creating a tissue bank called OmniBank, for the private fee-based, and public cryopreservation of the intact amnion tissue as based on the great worth and need for Mesenchymal stem cells for the future of Regenerative Medicine and the Cellular Therapy Industry. The Company has developed the best method of retrieving, preserving and isolating the Amnion Tissue and its' Mesenchymal Stem Cells by virtue of quality, and quantity, and driven by their proprietary technology of placental processing at birth, when the therapeutic value is at its’ maximum potential. The Company’s model of creating a High Definition Human Leukocyte Antigen (HLA) tissue matching database, will enable the world to also share the benefits of Amnion-Derived Stem Cells through matched allogeneic therapies, and truly drive both private and public stem cell banking to a new level. AmnioChor is inspired to make the OmniBank available to everyone.
AmnioChor further contemplates the OmniBank business model in a global context, and is currently engaged in establishing strategic relationships in the United States and Asia. The Company continues to develop the AmnioCept product with their Asian manufacturing affiliates, with commercialization validations conducted in both the US and Asia. With a second operational base being planned for Hong Kong, AmnioChor will also focus on the burgeoning markets of China, Singapore, Indonesia, Malaysia, Japan and India. With over 40 million births in China and India in 2014 alone, less than 1% chose to bank their stem cells.